Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy under-recognized subset of candidates for heart transplant

Circulation: Heart Failure

Volumn 7, Issue 6, 2014, Pages 967-975

  Rowin, Ethan J ^a   Maron, Barry J ^b   Kiernan, Michael S ^a   Casey, Susan A ^b   Feldman, David S ^b   Hryniewicz, Katarzyna M ^b   Chan, Raymond H ^c   Harris, Kevin M ^b   Udelson, James E ^a   DeNofrio, David ^a   Roberts, William C ^d   Maron, Martin S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diastolic dysfunction; Heart transplantation; Hypertrophic cardiomyopathy

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; MILRINONE; NITRATE; RANOLAZINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CHILD; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART GRAFT; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HOSPITAL ADMISSION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; TREATMENT OUTCOME; YOUNG ADULT; CARDIOMYOPATHY, HYPERTROPHIC; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; LUNG WEDGE PRESSURE; PATIENT SELECTION; SYSTOLE;

ADOLESCENT; ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PULMONARY WEDGE PRESSURE; SYSTOLE; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84920648748     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001435     Document Type: Article

References (35)

1. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381:242-255.
2. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783-e831.
3. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212-2218.
4. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35:2010-2020.
5. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA III, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverterdefibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-412.
6. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA III, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61:1527-1535.
7. Vriesendorp PA, Schinkel AF, Van Cleemput J, Willems R, Jordaens LJ, Theuns DA, van Slegtenhorst MA, de Ravel TJ, ten Cate FJ, Michels M. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J. 2013;166:496-502.
8. Olde Nordkamp LR, Wilde AA, Tijssen JG, Knops RE, van Dessel PF, de Groot JR. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention. Circ Arrhythm Electrophysiol. 2013;6:91-100.
9. Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, Bellini N, Smaniotto G, Zucchetto M, Iliceto S, Thiene G, Maron BJ. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31:2111-2123.
10. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295-303.
11. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470-476.
12. Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, Lennon RJ, Nishimura RA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126: 2374-2380.
13. Kato TS, Takayama H, Yoshizawa S, Marboe C, Schulze PC, Farr M, Naka Y, Mancini D, Maurer MS. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2012;110:568-574.
14. Biagini E, Spirito P, Leone O, Picchio FM, Coccolo F, Ragni L, Lofiego C, Grigioni F, Potena L, Rocchi G, Bacchi-Reggiani L, Boriani G, Prandstraller D, Arbustini E, Branzi A, Rapezzi C. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:387-392.
15. Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, Mackey-Bojack S, Manning WJ, Udelson JE, Maron BJ. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-225.
16. Fernández A, Vigliano CA, Casabé JH, Diez M, Favaloro LE, Guevara E, Favaloro RR, Laguens RP. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011;108:548-555.
17. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle ED; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.
18. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K, Barr M. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant. 2006;25:1024-1042.
19. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232-2239.
20. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-133.
21. Muthiah K, Phan J, Robson D, Macdonald PS, Keogh AM, Kotlyar E, Granger E, Dhital K, Spratt P, Jansz P, Hayward CS. Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case series. ASAIO J. 2013;59:183-187.
22. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:261-267.
23. Coutu M, Perrault LP, White M, Pelletier GB, Racine N, Poirier NC, Carrier M. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. J Heart Lung Transplant. 2004;23:413-417.
24. Gajarski R, Naftel DC, Pahl E, Alejos J, Pearce FB, Kirklin JK, Zamberlan M, Dipchand AI; Pediatric Heart Transplant Study Investigators. Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant. J Heart Lung Transplant. 2009;28:1329-1334.
25. Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:574-579.
26. Warren SE, Cohn LH, Schoen FJ, Mudge GH, Lorell BH. Advanced diatolic heart failure in familial hypertrophic cardiomyopathy managed with cardiac transplant. J Appl Cardiol 1988;3:415-422.
27. Roberts WC, Roberts CC, Ko JM, Grayburn PA, Tandon A, Kuiper JJ, Capehart JE, Hall SA. Dramatically different phenotypic expressions of hypertrophic cardiomyopathy in male cousins undergoing cardiac transplantation with identical disease-causing gene mutation. Am J Cardiol. 2013;111:1818-1822.
28. Rowin EJ, Maron MS. The ever expanding spectrum of phenotypic diversity in hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:463-464.
29. Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation. 2010;122:2441-2449; discussion 2450.
30. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705-715.
31. Garcia-Pavia P, Vázquez ME, Segovia J, Salas C, Avellana P, Gómez-Bueno M, Vilches C, Gallardo ME, Garesse R, Molano J, Bornstein B, Alonso-Pulpon L. Genetic basis of end-stage hypertrophic cardiomyopathy. Eur J Heart Fail. 2011;13:1193-1201.
32. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36:2219-2225.
33. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003;108:2342-2348.
34. Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, Lorenzini M, Terzi F, Bacchi-Reggiani L, Boriani G, Branzi A, Boni L, Rapezzi C. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol. 2009;104:1727-1731.
35. Maron BJ, Rastegar H, Udelson JE, Dearani JA, Maron MS. Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative. Am J Cardiol. 2013;112:1512-1515.